Fig. 3

Changes in body weight following treatment with DXR HCl liposome injections or placebo. The figure shows the change in body weight for: a syngeneic fibrosarcoma-bearing mice receiving SPIL DXR HCl liposome injection (n = 11), reference DXR HCl liposome injection (n = 15) or placebo (n = 15). One animal in the reference DXR HCl liposome group was found dead on Day 28; and b MX-1-bearing mice receiving SPIL DXR HCl liposome injection (1.5, 3 or 6 mg/kg); reference DXR HCl liposome injection (1.5, 3 or 6 mg/kg) or placebo (n = 10 per treatment group). Two animals in the 6 mg/kg SPIL DXR HCl liposome injection group were found dead, one on Day 28 and one on Day 35; two animals in the 6 mg/kg reference DXR HCl liposome group were found dead, one on Day 28 and one on Day 38. A dose producing a weight loss ≥15% of initial body weight was considered toxic. Body weight data were analysed by one-way analysis of variance followed by Dunnett’s t-test. **p < 0.01; ***p < 0.001; ns, non-significant compared with the SPIL DXR HCl liposome injection. Abbreviations: DXR, doxorubicin; HCl, hydrochloride; ns, non-significant; SPIL, Sun Pharmaceutical Industries Ltd.